Overview
HRMY market data
Price History
HRMY price chart
Valuation & Profitability
- P/E (TTM)
- 12.45 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.71 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.02 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 18.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $25.52 – $40.87 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.3B · P/B 2.48 · P/S 2.35.
Company News
Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $34Benzinga · Aug 5, 2026, 6:17 PM
Harmony Biosciences Says New Data Supports Neurology PipelineBenzinga · Aug 5, 2026, 10:56 AM
Needham Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $50Benzinga · Aug 4, 2026, 5:40 PM
Harmony Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 4, 2026, 3:20 PM
8-K filing — Harmony Biosciences Holdings, Inc. (HRMY)SEC EDGAR · Aug 4, 2026, 12:05 PM
Harmony Biosciences Q2 EPS $1.28 Beats $0.94 Estimate, Sales $261.300M Beat $248.406M EstimateBenzinga · Aug 4, 2026, 11:32 AM
Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B EstBenzinga · Aug 4, 2026, 11:30 AM
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51Benzinga · Jul 31, 2026, 5:39 PM
HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price TargetBenzinga · Jul 16, 2026, 4:24 PM
Harmony Biosciences Reports Preliminary Q2 WAKIX Sales Of ~$261M, Up 30% YoY; Appoints Stephen Mollichella As Interim CFOBenzinga · Jul 16, 2026, 12:40 PM